Mine Büker Özdemir1, Ertuğrul Karataş2, Mevlüt Albayrak3, Yasin Bayır4. 1. Department of Endodontics, Faculty of Dentistry, Ataturk University, 25240, Erzurum, Turkey. 2. Department of Endodontics, Faculty of Dentistry, Ataturk University, 25240, Erzurum, Turkey. dtertu@windowslive.com. 3. Erzurum High Vocational School of Health, Ataturk University, Erzurum, Turkey. 4. Department of Biochemistry, Faculty of Pharmacy Ataturk University, Erzurum, Turkey.
Abstract
OBJECTIVE: The aim of this study was to evaluate the effect of calcium hydroxide (Ca[OH]2) and chlorhexidine (CHX) gel on matrix metalloproteinase-9 (MMP-9) and vasoactive intestinal peptide (VIP) secretion in periapical lesions. MATERIALS AND METHODS:A total of 60 patients were randomly divided into two groups that were to receive different medications. Pre-and post-treatment samples were collected from the interstitial fluid of periapical lesions using sterile paper points. VIP and MMP-9 levels were measured by enzyme-linked immunosorbent assay kits, and the data were statistically analyzed. RESULTS: Gender and smoking habits had no effect on the pre- and post-treatment VIP and MMPs levels. Intragroup analyses revealed that in the Ca(OH)2 group, the post-treatment VIP level was found to be significantly higher than the pre-treatment VIP level. In the CHX group, the post-treatment MMP-9 level was significantly higher than the pre-treatment MMP-9 level. CONCLUSION: According to the results of the present study, the type of the medication affected the amount of periapical VIP and MMP-9 secretion. CLINICAL RELEVANCE: VIP is a neuropeptide that promotes new bone formation. Thus, intracanal Ca(OH)2 medication may accelerate the repair process of bone tissue.
RCT Entities:
OBJECTIVE: The aim of this study was to evaluate the effect of calcium hydroxide (Ca[OH]2) and chlorhexidine (CHX) gel on matrix metalloproteinase-9 (MMP-9) and vasoactive intestinal peptide (VIP) secretion in periapical lesions. MATERIALS AND METHODS: A total of 60 patients were randomly divided into two groups that were to receive different medications. Pre-and post-treatment samples were collected from the interstitial fluid of periapical lesions using sterile paper points. VIP and MMP-9 levels were measured by enzyme-linked immunosorbent assay kits, and the data were statistically analyzed. RESULTS: Gender and smoking habits had no effect on the pre- and post-treatment VIP and MMPs levels. Intragroup analyses revealed that in the Ca(OH)2 group, the post-treatment VIP level was found to be significantly higher than the pre-treatment VIP level. In the CHX group, the post-treatment MMP-9 level was significantly higher than the pre-treatment MMP-9 level. CONCLUSION: According to the results of the present study, the type of the medication affected the amount of periapical VIP and MMP-9 secretion. CLINICAL RELEVANCE: VIP is a neuropeptide that promotes new bone formation. Thus, intracanal Ca(OH)2 medication may accelerate the repair process of bone tissue.
Authors: J Caviedes-Bucheli; M M Azuero-Holguín; G C Moreno; I L González; E Mateu; J F Salazar; H R Munoz Journal: Int Endod J Date: 2007-05-18 Impact factor: 5.264
Authors: Frederico C Martinho; Cinthya C Gomes; Gustavo G Nascimento; Ana P M Gomes; Fábio R M Leite Journal: Clin Oral Investig Date: 2017-06-06 Impact factor: 3.573
Authors: Mauro V Corotti; Willian F Zambuzzi; Katiúcia B S Paiva; Renato Menezes; Lidiane C Pinto; Vanessa S Lara; José M Granjeiro Journal: Arch Oral Biol Date: 2009-06-03 Impact factor: 2.633